Evidence map›Paper›PMID 28774879›Full record

ArticleBlood2017

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu and 7 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06339255 (A Multicenter Prospective Observational Study on Chimeric Antigen Receptor), which is not on this map. Cited by 967 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
967citing papers in PubMed, 8 pooled it
75.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06339255 recruitingnot on this mapstarted 2019, after this paper: background citation

A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting

TypeobservationalSponsorPaolo CorradiniRan2019 to 2029Enrolled5,300ConditionsDiffuse Low Grade B-Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, Follicular Lymphoma
3 · Its place in the literature

Who cites it

967 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,636 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

907 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Michael CrumpCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Sattva S NeelapuDivision of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Umar FarooqDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA.
Eric Van Den NesteLymphoma Academic Research Organization, Pierre-Bénite, France.
John KuruvillaCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Jason WestinDivision of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Brian K LinkDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA.
Annette HayCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
James R CerhanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN; and.
Liting ZhuCanadian Cancer Trials Group, Queen's University, Kingston, ON, Canada.
Sami BoussettaLymphoma Academic Research Organization, Pierre-Bénite, France.
Lei FengDivision of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Matthew J MaurerDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN; and.
Lynn NavaleKite Pharma, Santa Monica, CA.
Jeff WiezorekKite Pharma, Santa Monica, CA.
William Y GoKite Pharma, Santa Monica, CA.
Christian GisselbrechtLymphoma Academic Research Organization, Pierre-Bénite, France.
Queen's University · CAKite (United States) · USThe Lymphoma Academic Research Organisation · FRThe University of Texas MD Anderson Cancer Center · USMayo Clinic in Florida · USUniversity of Iowa · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097274
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.

Indexed as

AdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansInternational CooperationLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMulticenter Studies as TopicObservational Studies as TopicRandomized Controlled Trials as TopicRetrospective StudiesSalvage TherapyTreatment Outcome

Identifiers

PMID28774879
PMCPMC5649550
OpenAlexW2744261860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.